
Brilliant Violet 785[™] anti-human TIGIT (VSTM3)

	2463680 / 100 tests 2463675 / 25 tests	SC DOB PE
Clone:	A15153G	
lsotype:	Mouse IgG2a, к	
Immunogen:	Recombinant Human TIGIT.	
Reactivity:	Human	
Preparation:	The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 785™ under optimal conditions.	
Formulation:	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)	Human perip lymphocytes CD3 PE and ⁻ A15153G) Bri
Workshop Number:	VI CD86.8	
Concentration:	Lot-specific	(left) or mous Violet 785™



Human peripheral blood lymphocytes were stained with CD3 PE and TIGIT (VSTM3) (clone A15153G) Brilliant Violet 785[™] (left) or mouse IgG2a, κ Brilliant Violet 785[™] isotype control (right).

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 μ L per million cells in 100 μ L staining volume or 5 μ L per 100 μ L of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 785[™] excites at 405 nm and emits at 785 nm. The bandpass filter 780/60 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 785[™] is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

ApplicationThis clone can suppress anti-CD3 induced T cell proliferation in vitro based
on in-house testing.

This clone has been tested in-house and determined to not be suitable for applications in immunohistochemistry of paraffin-embedded tissue sections (IHC-P).

Additional reported applications (for the relevant formats) include: Blocking¹.

Application References:	1. Stamm H, et al. 2018. Oncogene. Pubmed
Description:	T cell immunoreceptor with Ig and ITIM domains (TIGIT), also known as VSTM3 or WUCAM, is a 26 kD, type I transmembrane protein and is a member of the PVR (poliovirus receptor) family of immunoglobulin-like domain containing proteins. TIGIT is expressed on activated T cells, follicular T helper, memory, and regulatory T cells as well as on NK cells. TIGIT is a negative regulator of NK and T cell activation. Expression of TIGIT is associated with decreased functionality of CD8 T cells in chronic viral infection and tumors. TIGIT also promotes the differentiation of tolerogenic phenotype in dendritic cells with an increased secretion of IL-10 and a diminished production of IL-12.
Antigen References:	1. Stanietsky N, <i>et al.</i> 2009. <i>Proc. Natl. Acad. Sci.</i> 106:17858. 2. Yu X, <i>et al.</i> 2009. <i>Nat. Immunol.</i> 10:48. 3. Johnston R, <i>et al.</i> 2014. <i>Cancer Cell.</i> 26:923.